Shahar Harel, Head of AI at Quris, presented a BIO-AI approach to drug safety assessment using a 'patient-on-a-chip' platform. This platform simulates the human body and generates high-frequency microscopy and biochemical data on drug interactions, considering patient genomics and ethnicity. The data is used to train multimodal deep learning models to predict drug safety and provide patient-specific recommendations. Why it matters: This approach offers a potential alternative to animal models, promising faster and more personalized drug development while reducing safety concerns.
Zayed bin Hamad reviewed Sharjah Police's AI-led anti-drug drive, an initiative leveraging artificial intelligence to combat drug-related activities within the emirate. The review likely focused on assessing the technology's effectiveness and strategic implementation in enhancing public safety. This engagement underscores the ongoing efforts by UAE authorities to integrate advanced AI solutions into critical law enforcement operations. Why it matters: This highlights the increasing application of AI in public safety and law enforcement within the UAE, demonstrating a practical use case for national security and societal well-being.
KAUST researchers led by Dr. Niveen Khashab have developed thermosensitive liposomes for controlled drug release, particularly in cancer therapies. The liposomes are designed to release drugs only when they reach heated tumor tissue, minimizing systemic side effects. Cholesterol moieties are used as anchors to create a "nail" or "comb" effect, enabling temperature-triggered drug release inside cells. Why it matters: This targeted drug delivery system could significantly improve the efficacy and reduce the toxicity of cancer treatments.